Should I buy ArcBest Corp. (ARCB) stock or is it too late?
⭐ The most reliable of them, either direction: UBS — 63% of its targets hit on this sector (87 calls tested). It aims for $154 (+18 %), call made on August 4, 2026, maturing on August 4, 2027 (71 d ago).
Firm-by-firm track record on ArcBest Corp.
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Citigroup | 100 % | +42.0 % | 8 | $170 +30% |
| Stifel | 47 % | +30.4 % | 17 | $168 +29% |
| Morgan Stanley | 67 % | +27.9 % | 21 | $180 +38% |
| Truist Securities | 60 % | +26.8 % | 5 | $160 +23% |
| B of A Securities | 61 % | +10.0 % | 18 | $160 +23% |
| Credit Suisse | 100 % | +40.6 % | 6 | — |
| Stephens & Co. | 50 % | +12.1 % | 6 | — |
✅ Reasons to believe
- Median price target $160, i.e. +23% from the current price ($130).
- The most reliable firm on ARCB, Goldman Sachs (100% hit rate, 2 scored calls), targets $165 (call made on June 23, 2026, maturing on June 23, 2027) (+27%) in its most recent call, and $117 (call made on April 29, 2026, maturing on April 29, 2027) (-10%) in the one coming due soonest.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 11 ratings, 5 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on ARCB
Median target $160 (+23%) · 11 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in ArcBest Corp. now?
We won't decide for you. The facts: 55% of analysts rate it a buy, median target $160 (+23%), and Goldman Sachs (most reliable on ARCB, 100%) targets $165. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in ArcBest Corp.?
Not according to analysts: the median target ($160) is still +23% above the current price ($130) (most reliable on ARCB: Goldman Sachs, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is ArcBest Corp. still worth investing in?
It depends on the gap between the price ($130) and its estimated value: analysts target $160 on median (+23%), with 55% buys (most reliable on ARCB: Goldman Sachs, 100%). Cross-check with their real reliability on ARCB and the cautions above. Information, not advice.
What's the main risk in buying ARCB?
The consensus is not unanimous: of 11 ratings, 5 are neutral.
→ Go deeper: the full ArcBest Corp. profile (consensus, analyst reliability, price target, performance).